{"classes":[{"categories":[{"measurements":[{"comment":"Median, lower and upper limit of confidence interval could not be calculated because no participant had an event.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Due to small number of events, estimates (Median and upper limit of 95%confidence interval) from Kaplan-Meier survival curves could not be derived.","groupId":"OG001","lowerLimit":"9.00","upperLimit":"NA","value":"NA"},{"comment":"Due to small number of events, estimates (Median and upper limit of 95%confidence interval) from Kaplan-Meier survival curves could not be derived.","groupId":"OG002","lowerLimit":"4.24","upperLimit":"NA","value":"NA"},{"comment":"Due to small number of events, estimates (Median and upper limit of 95%confidence interval) from Kaplan-Meier survival curves could not be derived.","groupId":"OG003","lowerLimit":"4.17","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"14"}],"units":"Participants"}],"description":"Duration of response according to modified irRC, per investigator assessment was calculated for each participant with a confirmed response (immune-related complete response \\[irCR\\] or immune-related partial response \\[irPR\\]) as the time from the first observation of response to the first observation of documented disease progression (or death within 12 weeks of the last tumor assessment). irCR: Complete disappearance of all tumor lesions (both index and non-index lesions with no new measurable/unmeasurable lesions). irPR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions). Results were calculated based on Kaplan-Meier estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with ovarian carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG000","title":"Efficacy Expansion Cohort: Ovarian Cancer"},{"description":"Participants with urothelial carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG001","title":"Efficacy Expansion Cohort: Urothelial Carcinoma"},{"description":"Participants with gastric (GC) and gastroesophageal junction cancer (GEJC) who have failed both a first-line chemotherapy regimen and subsequent ramucirumab therapy, received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a third-line treatment in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG002","title":"Efficacy Expansion Cohort: GC/GEJC, Third Line"},{"description":"Participants with head and neck squamous cell carcinoma (HNSCC) received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG003","title":"Efficacy Expansion Cohort: HNSCC"}],"paramType":"MEDIAN","populationDescription":"FAS included all participants who have received at least 1 dose of study treatment. Here \"Overall number of participants analyzed\" signifies those who were evaluable for this outcome measure. This outcome measure was planned to be analyzed in Efficacy expansion cohorts only.","reportingStatus":"POSTED","timeFrame":"Efficacy Expansion: Baseline up to Day 1072","title":"Efficacy Expansion Cohorts: Duration of Response According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Per Independent Endpoint Review Committee (IERC)","type":"SECONDARY","unitOfMeasure":"Months"}